We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Review · February 19, 2021

Oxygenation and A2AR Blockade to Eliminate Hypoxia/HIF-1α–Adenosinergic Immunosuppressive Axis and Improve Cancer Immunotherapy

Current Opinion in Pharmacology

 

Additional Info

Current Opinion in Pharmacology
Oxygenation and A2AR Blockade to Eliminate Hypoxia/HIF-1α-Adenosinergic Immunosuppressive Axis and Improve Cancer Immunotherapy
Curr Opin Pharmacol 2020 Aug 01;53(xx)84-90, K Halpin-Veszeleiova, SM Hatfield

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading